Cancer ResearchClinical TrialPaywall

Nivolumab Plus Ipilimumab Tested in 67 Patients With Metastatic Uveal Melanoma

A completed phase II trial at MD Anderson tested dual checkpoint blockade in 67 patients with metastatic uveal melanoma. Results are not in the abstract.

Thursday, November 19, 2026 1 view
Published in cancer immunotherapy checkpoint
an oncology infusion room with an IV bag and pump beside a reclining patient chair

Summary

Uveal melanoma is a cancer of the eye that often spreads, usually to the liver, and it has historically responded poorly to treatment. This phase II trial from M.D. Anderson Cancer Center tested two immunotherapy antibodies together, nivolumab and ipilimumab, in 67 patients whose disease had spread. Both drugs work by releasing the brakes on the immune system so it can attack tumor cells. The trial began in November 2012 and is listed as completed in May 2024. The registry entry gives the design and enrollment but reports no outcomes, so we cannot say how many patients responded, how long they lived, or what side effects occurred. Biomarker analyses were part of the plan, which may help explain who benefits. For now this is a signal that the question was studied, not evidence that the combination works in this disease.

Detailed Summary

Cancer risk rises with age, and immune surveillance weakens as we get older, which makes immunotherapy a central topic for anyone following healthspan science. Uveal melanoma is a distinct cancer from skin melanoma and has been notably resistant to immune checkpoint drugs, so it is a hard test of the approach.

This entry describes a phase II trial run by M.D. Anderson Cancer Center. It enrolled 67 patients with metastatic, stage IV uveal melanoma. The intervention was nivolumab, which blocks the PD-1 checkpoint, combined with ipilimumab, which blocks CTLA-4. Both antibodies are intended to help T cells recognize and attack tumor cells. The protocol also included laboratory biomarker analysis.

The trial started on November 29, 2012 and is marked completed, with a completion date of May 14, 2024. The abstract available here is a registry description only. It does not report response rates, progression-free survival, overall survival, or adverse events. Nothing in it shows that the combination worked, failed, or caused harm. Any claim about efficacy would go beyond the available information.

What this means is limited. The existence of a completed, 67-patient trial shows that dual checkpoint blockade was seriously tested in a rare cancer with few options. Readers and clinicians should look for the published results, ideally including response rate, survival, toxicity (combination checkpoint therapy is known to cause immune-related side effects in other cancers) and any biomarkers that predict benefit. Those details will decide whether the regimen merits discussion with an oncologist.

The main caveats are that this summary relies on the registry abstract alone, that no outcome data are provided, and that a single-arm phase II design, if that is what was used, cannot prove benefit over other treatments. The mechanism is plausible, but plausibility is not a result.

Key Findings

  • Phase II trial enrolled 67 patients with metastatic stage IV uveal melanoma at M.D. Anderson Cancer Center.
  • Tested combined PD-1 blockade (nivolumab) and CTLA-4 blockade (ipilimumab), plus laboratory biomarker analysis.
  • Trial status is completed, with a completion date of May 2024.
  • The abstract reports no efficacy, survival or safety results, so no benefit or harm can be stated.

Methodology

Single-sponsor phase II interventional trial of nivolumab plus ipilimumab in 67 patients with metastatic uveal melanoma, started in 2012 and completed in 2024. Laboratory biomarker analysis was included. Randomization, arms and endpoints are not stated in the abstract.

Study Limitations

This summary is based on the abstract only, a registry description without results. No efficacy, survival, safety or biomarker findings are available, and the design details are not specified. Conclusions about whether the combination works cannot be drawn.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: